TL;DR: As of Aug. 27, you can get the premium Microsoft Office training bundle and

Yamaha has unveiled a self-riding electric motorbike that features no handlebars or other standard controls. The Yamaha Motoroid 2 is the next generation of the firm’s Motoroid concept bike first revealed in 2017, but unlike its predecessor, Yamaha has built a working prototype of the latest vehicle. The self-balancing bike features gyroscopes and image recognition AI systems to stay upright and navigate roads, while also being capable of riding itself without anyone aboard. “Motoroid 2 is a vehicle for personal mobility that can recognise its owner, get up off its kickstand and move alongside its rider,” the company said. “[It] has a distinctly lifelike feel when somebody is riding on its back and has a presence more like a lifetime companion.” Yamaha plans to show off the prototype of the Motoroid 2 at the Events Japan Mobility Show 2023 in Tokyo next month. It is not clear whether Yamaha plans to release a production model of the bike, however its continued development suggests that the automotive giant is working to integrate at least some of its features into future motorcycles. Self-driving technology is increasingly common in production vehicles, though it is currently limited to four-wheeled cars and trucks. Some have even considered eschewing steering wheels, with Tesla chief executive Elon Musk originally planning to build a fleet of self-driving electric taxis that have no visible user controls. The plan was reportedly sidelined after company executives noted that regulators in most major markets require steering wheels and pedals on vehicles. Several motorcycle manufacturers have unveiled concept bikes that require no rider to operate. BMW’s ConnectedRide retrofits the company’s R 1200 GS Adventure with autonomous technology to serve as a “testbed for advanced motorcycle safety” equipment that it hopes to introduce to its production models. “In a future world of autonomously driving cars, being connected will be an urgent requirement for all motorcycle segments,” BMW’s Markus Schramm said in 2020. “This will enhance safety and ensure that motorcycling remains future-proof.” Read More Reinventing the seatbelt for the self-driving era

Paige Spiranac's solo content is engrossing but she is also great at fan interaction videos

'Sister Wives' star Meri Brown faces backlash over excessive use of face tune which hides her real age as she shares selfie with friend

WASHINGTON--(BUSINESS WIRE)--Sep 20, 2023--

Our canine companions could soon be enjoying much longer lifespans, if a drug which claims it can extend dogs’ lives eventually gets approved. The drug, made by a tech firm in California, just cleared a vital hurdle to doing just that, after it got partial approval by regulators in the US. Loyal, a San Francisco-based company founded in 2020, has been researching how it can increase dogs’ lifespans – in particular larger breeds, which tend to die younger. Large and “giant” breeds tend to live to between eight and 12 years. Smaller dogs, such as Chihuahuas, can keep going to the ripe old age of 20. Loyal’s main product, the catchily-titled LOY-001, is designed not only to extend dogs’ lives but also maintain their quality of life. Now, it has passed the “reasonable expectation of effectiveness” test, set by regulators at the US’ Food and Drug Administration. Loyal’s chief executive, Celine Halioua, said: "Loyal was founded with the ambitious goal of developing the first drugs to extend healthy lifespan in dogs. "This milestone is the result of years of careful work by the team. We'll continue to work just as diligently to bring this and our other longevity programs through to FDA approval." Selective breeding of dogs has caused higher levels of hormones which help the animals grow faster. That is also believed to reduce their lifespan, the company said. Big dogs tend to have more of this hormone than their smaller counterparts. Animal rights activists are not yet convinced. Some experts fear it will only serve to extend animals’ suffering. Loyal, on the other hand, says the drug aims to treat doggy diseases which are associated with ageing through preventing them, rather than waiting for the animals to get sick before treating them. The company said that the drug could be available to US customers as early as 2026. So that’s plenty of time for walkies between now and then. How to join the indy100's free WhatsApp channel Sign up to our free indy100 weekly newsletter Have your say in our news democracy. Click the upvote icon at the top of the page to help raise this article through the indy100 rankings.

By Martin Coulter LONDON Two of the European Union's most senior officials plan to attend Britain's artificial intelligence

SAN JOSE, Calif.--(BUSINESS WIRE)--May 18, 2023--

MUNICH--(BUSINESS WIRE)--Jun 12, 2023--

BELLEVUE, Wash.--(BUSINESS WIRE)--Jul 5, 2023--

Shares of GameStop are plunging before the opening bell after the company fired CEO Matthew Furlong, the former Amazon executive that was brought in two years ago to turn the struggling video game retailer around

Andrew Tate stated that he gives $25 million a year and feeds children all across war-torn nations